SurgOptix, Inc.

Imagine if surgeons could see in vivo tumor margins during the operation with biology & light. Imagine an inexpensive new imaging technology that is safe for medical team and patient with no radioactivity, X-rays or high energy fields unlike PET, CT or MRI. Imagine if the specificity of in vivo imaging correlated to histopathology studies, enabling surgeons to see real-time pathology results during the procedure without waiting hours or days. Imagine if surgeons could reduce positive margins, reduce morbidity, reduce expensive repeat procedures and improve patient outcomes. Imagine how this advance in surgical imaging can enhance eyesight and palpation to improve the outcomes of 14 million people diagnosed each year with solid tumor cancers. Stop imagining, SurgOptix is here today. The functional prototypes and contrast agents have been demonstrated in first-in-human testing by our scientific advisors. The SurgOptix platform is well-suited to solid tumor cancers such as breast conserving surgery, as well as neurosurgery, colorectal, ovarian, prostate and skin cancers. Would you like to know more?

• Employees 1
• Founded 2009